AAPL322.01-6.20 (-1.89%) ▼|ABBV256.00-4.22 (-1.62%) ▼|ABT109.00+0.21 (+0.19%) ▲|ACN187.09-6.04 (-3.13%) ▼|ADBE268.59-17.16 (-6.01%) ▼|AMAT452.21+16.30 (+3.74%) ▲|AMD471.72+15.56 (+3.41%) ▲|AMGN436.90-7.22 (-1.63%) ▼|AMT175.81-1.94 (-1.09%) ▼|AMZN258.26-0.65 (-0.25%) ▼|AVGO356.28-0.88 (-0.25%) ▼|AXP326.71-3.11 (-0.94%) ▼|BA211.69+1.18 (+0.56%) ▲|BAC62.64-0.08 (-0.13%) ▼|BKNG193.63-1.50 (-0.77%) ▼|BLK1,121.80-4.35 (-0.39%) ▼|BMY66.65-1.44 (-2.11%) ▼|BNY165.23+0.90 (+0.55%) ▲|BRK-B505.99-2.14 (-0.42%) ▼|C137.72-0.42 (-0.30%) ▼|CAT810.20+10.06 (+1.26%) ▲|CL89.04-1.05 (-1.17%) ▼|CMCSA26.51-0.14 (-0.53%) ▼|COF219.19-1.31 (-0.59%) ▼|COP134.48-1.24 (-0.91%) ▼|COST917.72-7.70 (-0.83%) ▼|CRM260.49-3.94 (-1.49%) ▼|CSCO109.30+0.69 (+0.64%) ▲|CVS96.97-0.23 (-0.24%) ▼|CVX208.44-2.88 (-1.36%) ▼|DE695.87+1.46 (+0.21%) ▲|DHR207.45-3.58 (-1.70%) ▼|DIS105.76-1.40 (-1.31%) ▼|DUK120.26-1.14 (-0.94%) ▼|EMR152.49+2.28 (+1.51%) ▲|FDX321.96-2.36 (-0.73%) ▼|GD358.54-7.33 (-2.00%) ▼|GE336.44+2.96 (+0.89%) ▲|GEV941.39-0.46 (-0.05%) ▼|GILD150.41-0.81 (-0.54%) ▼|GM87.45+0.41 (+0.47%) ▲|GOOG336.11-2.97 (-0.87%) ▼|GOOGL339.36-2.90 (-0.85%) ▼|GS1,036.76-1.18 (-0.11%) ▼|HD321.52+3.45 (+1.08%) ▲|HON208.64+1.01 (+0.48%) ▲|IBM234.35-0.36 (-0.15%) ▼|INTC94.71+3.04 (+3.32%) ▲|INTU332.41-11.89 (-3.45%) ▼|ISRG366.92-2.92 (-0.79%) ▼|JNJ275.37-3.07 (-1.10%) ▼|JPM358.04-4.02 (-1.11%) ▼|KO88.04-0.77 (-0.87%) ▼|LIN478.46-3.74 (-0.77%) ▼|LLY1,142.99-16.61 (-1.43%) ▼|LMT524.92-8.03 (-1.51%) ▼|LOW205.05+3.15 (+1.56%) ▲|LRCX303.28+10.62 (+3.63%) ▲|MA581.09-4.62 (-0.79%) ▼|MCD256.62-3.01 (-1.16%) ▼|MDLZ61.48+0.03 (+0.04%) ▲|MDT94.32+1.22 (+1.31%) ▲|META615.44+4.76 (+0.78%) ▲|MMM168.37+0.06 (+0.03%) ▲|MO69.00-0.50 (-0.71%) ▼|MRK150.28-2.06 (-1.35%) ▼|MS217.02-0.13 (-0.06%) ▼|MSFT500.11-10.01 (-1.96%) ▼|MU1,003.46+45.30 (+4.73%) ▲|NEE83.42-0.64 (-0.76%) ▼|NFLX78.76-3.92 (-4.74%) ▼|NKE38.57-0.21 (-0.53%) ▼|NOW141.24-4.35 (-2.99%) ▼|NVDA229.89+1.44 (+0.63%) ▲|ORCL156.89+2.85 (+1.85%) ▲|PEP137.85-0.70 (-0.50%) ▼|PFE28.42-0.39 (-1.35%) ▼|PG146.32-0.61 (-0.41%) ▼|PLTR174.25-8.28 (-4.54%) ▼|PM182.65-3.52 (-1.89%) ▼|QCOM167.28-1.29 (-0.77%) ▼|RTX200.65-1.48 (-0.73%) ▼|SBUX104.87-0.95 (-0.90%) ▼|SCHW109.47-0.91 (-0.82%) ▼|SO87.96-0.82 (-0.92%) ▼|SPG210.17-1.35 (-0.64%) ▼|T25.78-0.42 (-1.58%) ▼|TMO612.37-6.06 (-0.98%) ▼|TMUS182.89-5.13 (-2.73%) ▼|TSLA354.76-21.61 (-5.74%) ▼|TXN257.59+3.76 (+1.48%) ▲|UBER76.41+0.45 (+0.59%) ▲|UNH395.68-5.26 (-1.31%) ▼|UNP289.99+0.84 (+0.29%) ▲|UPS102.41-1.10 (-1.06%) ▼|USB63.37-0.17 (-0.26%) ▼|V374.63-4.12 (-1.09%) ▼|VZ50.27-0.33 (-0.64%) ▼|WFC89.82+0.63 (+0.71%) ▲|WMT107.32-1.10 (-1.01%) ▼|XOM159.78-2.44 (-1.50%) ▼|AAPL322.01-6.20 (-1.89%) ▼|ABBV256.00-4.22 (-1.62%) ▼|ABT109.00+0.21 (+0.19%) ▲|ACN187.09-6.04 (-3.13%) ▼|ADBE268.59-17.16 (-6.01%) ▼|AMAT452.21+16.30 (+3.74%) ▲|AMD471.72+15.56 (+3.41%) ▲|AMGN436.90-7.22 (-1.63%) ▼|AMT175.81-1.94 (-1.09%) ▼|AMZN258.26-0.65 (-0.25%) ▼|AVGO356.28-0.88 (-0.25%) ▼|AXP326.71-3.11 (-0.94%) ▼|BA211.69+1.18 (+0.56%) ▲|BAC62.64-0.08 (-0.13%) ▼|BKNG193.63-1.50 (-0.77%) ▼|BLK1,121.80-4.35 (-0.39%) ▼|BMY66.65-1.44 (-2.11%) ▼|BNY165.23+0.90 (+0.55%) ▲|BRK-B505.99-2.14 (-0.42%) ▼|C137.72-0.42 (-0.30%) ▼|CAT810.20+10.06 (+1.26%) ▲|CL89.04-1.05 (-1.17%) ▼|CMCSA26.51-0.14 (-0.53%) ▼|COF219.19-1.31 (-0.59%) ▼|COP134.48-1.24 (-0.91%) ▼|COST917.72-7.70 (-0.83%) ▼|CRM260.49-3.94 (-1.49%) ▼|CSCO109.30+0.69 (+0.64%) ▲|CVS96.97-0.23 (-0.24%) ▼|CVX208.44-2.88 (-1.36%) ▼|DE695.87+1.46 (+0.21%) ▲|DHR207.45-3.58 (-1.70%) ▼|DIS105.76-1.40 (-1.31%) ▼|DUK120.26-1.14 (-0.94%) ▼|EMR152.49+2.28 (+1.51%) ▲|FDX321.96-2.36 (-0.73%) ▼|GD358.54-7.33 (-2.00%) ▼|GE336.44+2.96 (+0.89%) ▲|GEV941.39-0.46 (-0.05%) ▼|GILD150.41-0.81 (-0.54%) ▼|GM87.45+0.41 (+0.47%) ▲|GOOG336.11-2.97 (-0.87%) ▼|GOOGL339.36-2.90 (-0.85%) ▼|GS1,036.76-1.18 (-0.11%) ▼|HD321.52+3.45 (+1.08%) ▲|HON208.64+1.01 (+0.48%) ▲|IBM234.35-0.36 (-0.15%) ▼|INTC94.71+3.04 (+3.32%) ▲|INTU332.41-11.89 (-3.45%) ▼|ISRG366.92-2.92 (-0.79%) ▼|JNJ275.37-3.07 (-1.10%) ▼|JPM358.04-4.02 (-1.11%) ▼|KO88.04-0.77 (-0.87%) ▼|LIN478.46-3.74 (-0.77%) ▼|LLY1,142.99-16.61 (-1.43%) ▼|LMT524.92-8.03 (-1.51%) ▼|LOW205.05+3.15 (+1.56%) ▲|LRCX303.28+10.62 (+3.63%) ▲|MA581.09-4.62 (-0.79%) ▼|MCD256.62-3.01 (-1.16%) ▼|MDLZ61.48+0.03 (+0.04%) ▲|MDT94.32+1.22 (+1.31%) ▲|META615.44+4.76 (+0.78%) ▲|MMM168.37+0.06 (+0.03%) ▲|MO69.00-0.50 (-0.71%) ▼|MRK150.28-2.06 (-1.35%) ▼|MS217.02-0.13 (-0.06%) ▼|MSFT500.11-10.01 (-1.96%) ▼|MU1,003.46+45.30 (+4.73%) ▲|NEE83.42-0.64 (-0.76%) ▼|NFLX78.76-3.92 (-4.74%) ▼|NKE38.57-0.21 (-0.53%) ▼|NOW141.24-4.35 (-2.99%) ▼|NVDA229.89+1.44 (+0.63%) ▲|ORCL156.89+2.85 (+1.85%) ▲|PEP137.85-0.70 (-0.50%) ▼|PFE28.42-0.39 (-1.35%) ▼|PG146.32-0.61 (-0.41%) ▼|PLTR174.25-8.28 (-4.54%) ▼|PM182.65-3.52 (-1.89%) ▼|QCOM167.28-1.29 (-0.77%) ▼|RTX200.65-1.48 (-0.73%) ▼|SBUX104.87-0.95 (-0.90%) ▼|SCHW109.47-0.91 (-0.82%) ▼|SO87.96-0.82 (-0.92%) ▼|SPG210.17-1.35 (-0.64%) ▼|T25.78-0.42 (-1.58%) ▼|TMO612.37-6.06 (-0.98%) ▼|TMUS182.89-5.13 (-2.73%) ▼|TSLA354.76-21.61 (-5.74%) ▼|TXN257.59+3.76 (+1.48%) ▲|UBER76.41+0.45 (+0.59%) ▲|UNH395.68-5.26 (-1.31%) ▼|UNP289.99+0.84 (+0.29%) ▲|UPS102.41-1.10 (-1.06%) ▼|USB63.37-0.17 (-0.26%) ▼|V374.63-4.12 (-1.09%) ▼|VZ50.27-0.33 (-0.64%) ▼|WFC89.82+0.63 (+0.71%) ▲|WMT107.32-1.10 (-1.01%) ▼|XOM159.78-2.44 (-1.50%) ▼|
29.8 C
New York
Friday, September 4, 2026

Tag: action

newssourceFORcompanyinformationcontent1releasesmarket

ACADIA HEALTHCARE ALERT: Bragar Eagel & Squire, P.C. is Investigating Acadia Healthcare Company, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact...

If you purchased or acquired stock in Acadia between February 28, 2020 to October 30, 2024 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648.

ATKORE INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Atkore Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Atkore (ATKR)To Contact Him Directly To Discuss Their Options

Fiserv, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. September 22, 2025 Deadline to file Lead Plaintiff Motion.

Investors can contact the law firm at no cost to learn more about recovering their losses

Tivity Health, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. October 20, 2025 Deadline to file Lead Plaintiff Motion

Investors can contact the law firm at no cost to learn more about recovering their losses

Skechers U.S.A., Inc. Investors: Company Investigated by the Portnoy Law Firm

Investors can contact the law firm at no cost to learn more about recovering their losses

Barnes & Noble Education, Inc. Investors: Company Investigated by the Portnoy Law Firm

Investors can contact the law firm at no cost to learn more about recovering their losses

Calidi announces Reverse Stock Split, expected to begin trading on a 1-for-12 split adjusted basis on August 5, 2025

SAN DIEGO, July 25, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (“Calidi” or the “Company”) (NYSE American: CLDI), a clinical-stage biotechnology company pioneering the development of targeted therapies with the potential to deliver genetic medicines to distal sites of disease, announced today that it will effect a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-12 (the “Reverse Stock Split”). The Company’s common stock is expected to commence trading on a split-adjusted basis when the NYSE American market opens on August 5, 2025 under the existing symbol of “CLDI.” The new CUSIP number for the Company’s common stock following the Reverse Stock Split will be 320703 408.

Celcuity to Announce Topline Results for the PIK3CA Wild-Type Cohort from Phase 3 VIKTORIA-1 Trial in HR+/HER2- Advanced Breast Cancer

MINNEAPOLIS, July 25, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced the Company will hold a conference call and webcast on Monday, July 28, 2025 at 8:00 AM ET to disclose the topline results of the PIK3CA Wild-Type Cohort from the Phase 3 VIKTORIA-1 trial.

Recognify Life Sciences Provides Update on Phase 2b Trial of Inidascamine in Patients with Cognitive Impairment Associated with Schizophrenia

SOUTH SAN FRANCISCO, July 25, 2025 (GLOBE NEWSWIRE) -- Recognify Life Sciences, a clinical-stage biotech company focused on developing treatments for cognitive impairment, today announced that its randomized, double-blind, placebo-controlled Phase 2b clinical trial evaluating inidascamine (formerly RL-007) in patients with cognitive impairment associated with schizophrenia (CIAS) did not meet its primary endpoint.

CAPR Class Action Alert: Robbins LLP Reminds Investors of the Lead Plaintiff Deadline in the Capricor Therapeutics, Inc. Securities Class Action

Robbins LLP is Investigating Allegations that Capricorn Therapeutics, Inc. (CAPR) Misled Investors Regarding the Viability of Deramiocel

Gundam Wing 30th Anniversary Shines at San Diego Comic-Con 2025

SDCC Panel Unveils Major Milestones for the Franchise That Brought Gundam to America and Sets the Stage for What's Next LOS ANGELES, July 25, 2025...

Amare Global Launches Skin to Mind™: Skincare Built on Neuroscience + Made with Mental Wellness in Mind

Revolutionary formulas target visible stress signals and support bliss signals at the cutaneous level for results you can see on your skin—and feel within. NEW...

Activité T2 et résultats financiers S1 2025

COMMUNIQUÉ DE PRESSE

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sarepta Therapeutics

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Sarepta To Contact Him Directly To Discuss Their Options

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsAction

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers